KI, Karolinska University Hospital and AstraZeneca are entering into a tripartite collaboration to promote the development of precision medicine in Sweden. The ambition is that patients throughout the country will have access to tailored prevention, diagnosis, treatment and follow-up.
“Close collaboration with industry is essential for the development and implementation of precision medicine,” says Anna Martling, Professor of Surgery and Scientific Director Life Science, Karolinska Institutet.
Precision medicine means individually designed prevention, diagnosis, treatment and follow-up based on the patient’s unique information, such as genetic profile, specific biomarkers, lifestyle and surrounding environment. This means better chances of getting the right treatment to the right patient at the right time.
With precision medicine as an integral part of routine care, more patients can have faster access to new and innovative treatments. The goal is better treatments for patients and greater socio-economic benefit.
The next step in the collaboration will be to refine strategic priorities and launch projects for deeper collaboration.
